Welcome to our dedicated page for Humana SEC filings (Ticker: HUM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Humana Inc. filings document formal disclosures for a public healthcare company with Humana insurance services and CenterWell healthcare services. Recent 8-K reports cover quarterly results, GAAP and non-GAAP earnings measures, Insurance segment benefit ratio commentary, Medicare Advantage membership assumptions, Regulation FD communications, and guidance updates.
Humana's SEC records also include proxy and annual-meeting materials covering director elections, auditor ratification, stockholder voting results, board composition, and director compensation program disclosures; board and executive transition disclosures; and capital-structure filings for registered debt offerings, including junior subordinated notes described through Form S-3 and prospectus-supplement materials.
Shetty Sanjay K reported acquisition or exercise transactions in this Form 4 filing.
Humana Inc. President, CenterWell Sanjay K. Shetty received a grant of 9,945 shares of Humana Common stock as compensation. The shares were awarded at a price of $0.0000 per share and increase his directly held common stock position to 22,088 shares.
The filing also shows he holds stock options giving the right to buy 6,572 Humana shares at $367.21 per share expiring on February 21, 2031, and 3,964 shares at $487.1602 per share expiring on April 1, 2030. His reported holdings include 18,763 restricted stock units that can settle into Humana common shares.
Humana Inc. executive Aaron Martin received a grant of 8,206 shares of Humana common stock as a compensation award. The award was recorded at a price of $0.0000 per share and classified as a grant or other acquisition rather than an open-market purchase.
Following this transaction, Martin directly holds 25,237 restricted stock units, each representing a contingent right to receive one share of Humana Inc. common stock. These units were granted under the company’s 2019 Amended & Restated and 2026 Stock Incentive Plans and are exempt under Rule 16b-3.
Vanguard Capital Management reports beneficial ownership of 9,068,300 shares of Humana Inc Common Stock, representing 7.55% of the class as of 03/31/2026. The filer discloses sole voting power of 1,229,538 shares and sole dispositive power over 9,068,300 shares. The filing states these holdings include shares held for Vanguard funds and managed accounts and attributes voting/dispositive arrangements to Vanguard affiliates.
Humana Inc. reported first quarter 2026 revenue of $39.6 billion, up from $32.1 billion a year earlier, with GAAP diluted EPS of $9.83 versus $10.30 and Adjusted EPS of $10.31 versus $11.58. The Insurance segment benefit ratio was 89.4%, slightly better than guidance of “just under 90%,” while the consolidated operating cost ratio improved to 10.2% (10.0% Adjusted). Operating cash flow rose to $1.25 billion from $331 million. For full-year 2026, Humana cut GAAP EPS guidance to at least $8.36 from $8.89 but reaffirmed Adjusted EPS guidance of at least $9.00 and expects individual Medicare Advantage membership to grow about 25%. The CenterWell segment delivered revenue growth to $6.1 billion but faced higher operating cost ratios as it absorbed recent acquisitions and risk-model changes.
Humana Inc. director Robert Stuart Field filed an initial Form 3 reporting his beneficial ownership of Humana Common stock. The filing shows a holding entry dated April 16, 2026 with 0 shares of Humana Common held directly after the reported event, and no buy or sell transactions.
Humana Inc. held its annual shareholder meeting on April 16, 2026, where all ten director nominees were elected to the board. A quorum was present, with 107,941,773 common shares represented by valid proxy.
Shareholders approved the ratification of PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026, supported the non-binding advisory vote on executive compensation, and approved the Humana Inc. 2026 Stock Incentive Plan. A shareholder proposal seeking a shareholder approval requirement for excessive golden parachutes did not pass.
Humana Inc. expanded its Board of Directors from ten to eleven members and elected Robert S. Field as a director, effective immediately following the Company’s 2026 Annual Meeting of Stockholders on April 16, 2026.
The Board determined that Field qualifies as an independent director under New York Stock Exchange standards. He will participate in Humana’s standard director compensation program and receive restricted stock units in connection with his election. Field is Principal and Managing Member of ηMed Capital Management LLC and brings more than two decades of healthcare investment, strategy, and legal experience. His appointment followed a Board-led search process informed by shareholder engagement.
Humana Inc. President, CenterWell, Sanjay K. Shetty reported equity compensation activity. On April 1, 2026, he acquired 887 shares of Humana common stock through the exercise or settlement of performance-related equity awards. On the same date, 401 shares at $175.44 per share were withheld to cover tax liabilities on performance stock vesting, with no sale proceeds received.
After these transactions, Shetty directly owns 12,143 Humana common shares, which include 8,818 restricted stock units and additional Performance Stock Units. He also holds stock options over 3,964 underlying shares at an exercise price of $487.1602 expiring on April 1, 2030, and options over 6,572 underlying shares at $367.21 expiring on February 21, 2031.
Humana Inc. President, Insurance George Renaudin reported routine compensation-related activity, including an annual contribution of 25 Phantom Stock Units based on Humana common stock at $173.39 per unit under the Humana Retirement Equalization Plan.
Following the update, he holds 199 Phantom Stock Units indirectly, 16,075 shares of Humana common stock directly and 542 shares indirectly through a retirement savings plan. He also holds stock options on 4,162 shares at an exercise price of $510.2425 expiring in 2030 and options on 6,966 shares at $367.21 expiring in 2031, plus 9,059 restricted stock units that may convert into common shares.